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INTRODUCTION
The scientific and regulatory focus con-
cerning the effects of chronic inorganic ar-
senic exposure has been on its carcinogenic
properties. Likewise, epidemiologic re-
views have dealt with cancer but not with
vascular diseases (1, 2). Many studies con-
cerning the vascular effects of arsenic have
been published, but no synthesis of findings
has been presented.
Reports of vascular effects of arsenic,
which span almost 100 years, vary with
respect to the sources and routes of expo-
sure, the specific disease entities described,
and the informativeness of the findings. In
this review, we present and summarize the
available data on the vascular effects of
chronic arsenic exposure and assess the ev-
idence for causality. First, we group and
discuss the studies according to the source
of exposure: drinking water, wine substi-
tutes, air, and medications. Next, we de-
scribe the important similarities and dis-
crepancies between the findings from
different sources of exposure and different
exposed groups. Finally, we propose pos-
sible explanations for the epidemiologic
findings.
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ARSENIC IN DRINKING WATER
Blackfoot disease endemic area,
Taiwan
An area along the southwestern coast of
Taiwan is known for the endemic occur-
rence of a peripheral vascular disease, lo-
cally known as Wu Chiao Ping, which
translates into "blackfoot disease" (3), and
which reached a prevalence of nine per
1,000 in the endemic area in the early 1960s
(4). Early investigations of blackfoot dis-
ease (5-12) were followed by additional
epidemiologic studies concerning cancer
(4, 13-20) and cardiovascular diseases (17,
20), as well as further studies of blackfoot
disease (3, 4, 13, 14, 20, 21).
Blackfoot disease
Blackfoot disease starts most often with
numbness or coldness in a limb and inter-
mittent claudication (7). The toes and feet
are primarily involved, with occasional oc-
currence in the fingers (3). Onset and ex-
acerbation are associated with cold weather
and injuries (3, 7, 21). The agonizingly
painful condition ultimately progresses to
gangrene, and resulted in spontaneous or
surgical amputation in 68 percent of 1,300
blackfoot disease patients in one study (21).
Among these patients, age at onset of
symptoms ranged from 2 years to 87 years,
with 28 percent of patients being under the
age of 40 years (21). An earlier study of
327 patients indicated that gangrene devel-
oped within a few months to 2 years after
disease onset (7). The duration between the
first signs of gangrene and spontaneous am-
putation was between less than 1 month and
2 years (21). The male:female ratio was 3:2
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(21), and female patients tended to be
younger than male patients (3, 21).
Based on the series of 327 patients, pul-
sation of affected arteries in the feet was
still present in 38.5 percent of arteria dor-
salis pedis and in 38.9 percent of arteria
tibialis posterior (7). Arteriography was
performed on five cases which all showed
marked narrowing of major arteries in legs
and arms (7). Histologically, thromboangi-
itis obliterans and arteriosclerosis obliter-
ans have been observed (22). In an early
stage of blackfoot disease, thickening and
fibrinoid degeneration of the blood vessel
wall and perivascular small round cell in-
filtration of the affected skin have been
described (23). Gangrenous limbs showed
proliferation and dilation of the dermal ves-
sels and occlusion of subcutaneous arte-
rioles with thrombosis and proliferation of
their vasa vasorum (23).
Based on the memory of older residents,
blackfoot disease first occurred in the years
following the consumption of water from
deep (artesian) wells (9, 24) which came
into use between 1900 and 1930 (3). Be-
cause of their high salinity (5), shallow
wells were replaced by these deep wells. It
was noted in the 1950s that the distribution
of blackfoot disease and the use of deep
well water coincided, and an early study (9)
established an association between con-
sumption of artesian well water and occur-
rence of blackfoot disease on an ecologic
level. It was also noted that five blackfoot
disease patients residing in nonendemic ar-
eas, where no artesian wells were used, had
migrated away from the endemic area 2
years prior to the onset of the disease (9). A
physicochemical study of artesian well wa-
ter in the affected area found it to contain
high levels of arsenic (8). Thus, arsenic was
suspected as the main cause of blackfoot
disease.
Case-control studies. The first case-
control study included 353 prevalent cases
of blackfoot disease and 353 controls (3).
The findings are summarized in table 1.
Consumption of deep well water during
the 15 years preceding the onset of dis-
ease was found in all of the cases and in
66 percent of the controls (p < 0.0001).
Among subjects exposed to deep well wa-
ter, the risk was related to the duration of
its consumption.
Another case-control study of 241 black-
foot disease patients and 759 controls con-
firmed the relation between use of deep
well water and development of the disease,
and found a clear association using a sur-
rogate measure of cumulative arsenic expo-
sure (20). Long-term arsenic poisoning was
identified by keratosis or cancer of the skin,
two well known effects of chronic arsenic
exposure. Logistic regression yielded in-
creased odds ratios for years of use of ar-
tesian well water and signs of arsenic poi-
soning (table 1).
Socioeconomic variables, smoking, nu-
trition, and family history of blackfoot dis-
ease were also investigated in the two case-
control studies (table 1). Socioeconomic
status and education were associated with
disease in the first study (3), but no associ-
ation was found with education in the sec-
ond investigation (20). Smoking is not a
necessary cause of the disease, because al-
most no female blackfoot disease patients
and only about half of the male patients
were smokers (3), nor did smoking differ
between cases and controls in either of the
two studies. The negative results may indi-
cate that blackfoot disease is primarily a
small vessel peripheral artery disease which
does not share the traditional risk factors of
cardiovascular diseases (25). The marginal
nutritional status of the population did not
differ between cases and controls in one
study (3). However, nutrition was found to
be important in the study by Chen et al.
(20), where high consumption of dried
sweet potatoes and low consumption of
eggs, meat, and vegetables were associated
with increased risk of blackfoot disease.
The negative finding in the first case may
have been due to a lack of variation in the
source population rather than a lack of im-
portance of nutritional status. Although a
family history of blackfoot disease was as-
sociated with higher risk, only 14 of 241
cases were classified as having a family
history based on numbers of affected and
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TABLE 1. Case-control studies of blackfoot disease in Taiwan
Case-control study
Ch'i and Blackwell (3) Chen et al. (20)
Subjects
Variables
Deep well water
Arsenic
Cigarette smoking
Nutrition
353 prevalent blackfoot disease patients;
353 sex, age, and district matched
controls
Consumption during 15 years prior to
disease onset: all 353 cases, 233
(66%) controls (p < 0.0001)*
Among subjects consuming deep well
water, period of consumption of
more vs. less than 10 years: OR =
2.58 (95% Clt 1.47-4.61)*
Not investigated
Males, overall, OR = 0.88 (95% Cl
0.57-1.35)*
Disease onset < 30 years, OR = 2.15
(95% Cl 0.69-6.90)*
Disease onset > 30 years, OR = 0.73
(95% Cl 0.46-1.18)*
No data but text mentions absence of
association
Family history
Socioeconomic
status
Not investigated
Among subjects with deep well water as
principle source, levels of socio-
economic status:
Above average, OR = 1
Average, OR = 3.30
Below average, OR = 4.55
Trend test, p< 0.0001*
No vs. some education: OR = 1.48
(95% Cl 1.02-2.15)*
241 prevalent blackfoot disease
patients; 759 sex, age, and
township matched controls
Odds ratiosf for years of consumption:
0 years, ORJ = 1.00;
1-29 years, OR = 3.04;
>30 years, OR = 3.47;
Trend-test, p< 0.001
Cutaneous signs of arsenic poisoning
(keratoses or cancer): yes vs. no,
= 2.77(p< 0.01)
Yes vs. no, OR = 0.87 (95% Cl
0.62-1.2)*
Sweet potato vs. rice: ORt = 1.90 (p <
0.05);
Vegetable consumption: <7 vs. 7 days/
week; ORt = 143 (p< 0.05)
Egg consumption:
£4 days/week, ORt = 1.00;
1-3 days/week, ORt = 2.08;
<1 day/week, ORt = 2.30;
trend test, p<0.01§
Meat consumption:
>4 days/week, ORt = 1.00;
1-3 days/week, ORt = 1.30;
<1 day/week, ORt = 1.57;
trend test not significantl
Yes vs. no|, ORt = 3.29 (p < 0.01)
Formal education, yes vs. no:
ORt = 1.03 (not significant)!
• Calculated from data.
t Adjusted odds ratios (logistic regression).
% OR, odds ratio; Cl, confidence interval.
§ In Chen et al. (20), the p value 0 "<0.10" in table 4 is probably an error, the univariate trend test (table 3) gives p < 0.01.
I Alpha level not indicated.
1) Based on numbers of affected and unaffected first-degree relatives, criteria for the variable 'family history" not indicated.
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unaffected first-degree relatives (20). Fur-
thermore, the study was not designed to
disentangle environmental and genetic in-
fluences. The adjustment for arsenic con-
sumption was based on the presence or
absence of chronic arsenicalism, thus leav-
ing room for residual confounding in as-
sessing family history.
The co-occurrence of blackfoot disease
with bladder, kidney, and skin cancer. It
has been established that ingestion of inor-
ganic arsenic causes skin cancer (26). There
is also evidence that ingestion of inorganic
arsenic can cause internal cancers. Bates
et al. (2) reviewed the evidence for cau-
sality in detail, and a risk assessment us-
ing data from Taiwan provides quantita-
tive risk estimates under the assumption
of causality (27). The steepest dose-re-
sponse gradients were observed for blad-
der and kidney cancers.
An excess co-occurrence of blackfoot
disease with these cancers (or with cutane-
ous signs of chronic arsenicalism) would be
expected if arsenic were a cause of both
blackfoot disease and these cancers. In a
cross-sectional survey of 40,421 persons
in the blackfoot disease endemic area, the
co-occurrence of blackfoot disease with
skin cancer and with keratosis (a sign of
arsenicalism) was far beyond what was
expected under stochastic independence
(13) (table 2).
An ecologic investigation examined can-
cer mortality in the blackfoot disease en-
demic area and the association between
cancer mortality and prevalence rates of
blackfoot disease (table 2) (14). High stan-
dardized mortality ratios for skin, bladder,
and kidney cancer were observed in both
sexes in the blackfoot disease endemic area
compared with the general Taiwanese pop-
ulation. Standardized mortality ratios
ranged from 5.34 for skin cancer in males
to 20.09 for bladder cancer in females. Af-
ter villages were grouped according to three
categories of blackfoot disease prevalence
rates, "dose-response" patterns emerged for
the standardized mortality ratios of the
three cancers, although no measure of pre-
cision or formal statistical analyses were
presented for the relations.
A retrospective cohort study of 871
blackfoot disease patients investigated their
mortality experience between 1968 and
1983 (20) (table 2). Compared with mortal-
ity rates in the blackfoot disease endemic
area, blackfoot disease patients showed
age- and sex-adjusted standardized mortal-
ity ratios of 1.60, 2.55, and 4.51 for kidney,
bladder, and skin cancer, respectively.
Arsenic in deep well water and preva-
lence of blackfoot disease. A cross-sec-
tional survey of 40,421 persons related the
prevalence rates of blackfoot disease to the
quantitative arsenic content in well water at
the village level (4). We statistically related
arsenic levels to blackfoot disease preva-
lence rates based on data from the paper of
Tseng (ref. 4, figure 6), which provides
age- and sex-specific prevalence rates of
blackfoot disease for four groups of vil-
lages according to the arsenic level in well
water (low, medium, high, and unknown).
Average arsenic concentrations for the first
three groups have been estimated as 170,
470, and 800 /xg/liter (28). Estimates of the
population at risk (28) specific to sex, age
group, and arsenic level are shown in table
3. The age- and sex-specific prevalence
rates and population estimates were used to
calculate the number of cases in each stra-
tum which, together with the population
number, allowed the use of the Mantel ex-
tension for the overall trend (29). The trend
tests were significant for both females and
males (p < 0.001) across the three arsenic
categories using three age strata (table 3).
Assessment of the roles of deep well wa-
ter and arsenic in blackfoot disease. The
epidemiologic data indicate that consump-
tion of deep well water is associated with
blackfoot disease in Taiwan. The "effect"
of this artesian water was so large that the
association had been perceived by the pop-
ulation itself. The two case-control studies
described above support a possible causal
role of deep well water in blackfoot disease
by both large measures of effect and dose-
response relations. Consumption of the
drinking water may even be a necessary
cause, since in one study all cases were
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TABLE 2. Studies of the co-occurrence of blackfoot disease with bladder, kidney, and skin cancer
Study
(reference no.) Study design Study subjects Results
Tseng etal. (13) Cross-sectional,
1963-1965
Survey of 40,421 persons
in blackfoot disease
endemic area
Chen etal. (14) Ecologic Mortality period 1968-1982
Chen et al. (20) Cohort Mortality experience of
871 blackfoot disease
patients, 1968-1983
Co-occurrence of blackfoot disease and
skin cancer: observed, 61;
expected,* 4; observed/expected,
16.77
Co-occurrence of blackfoot disease and
keratosis: observed, 135;
expected/ 26; observed/expected,
5.3
Co-occurrence of blackfoot disease,
skin cancer, and keratosis:
observed, 46; expected,* 0.3;
observed/expected, 162.85
Age adjusted SMRt in blackfoot disease
area (Taiwan rates as reference)
Bladder cancer: male, SMR = 11
(95% Clf 9.33-12.67); female,
SMR = 20.09 (95% Cl 17.02-23.16)
Kidney cancer: male, SMR = 7.72
(95% Cl 5.37-10.07); female, SMR
= 11.19 (95% Cl 8.38-14.00)
Skin cancer: male, SMR = 5.34 (95%
Cl 3.79-6.89); female, SMR = 6.52
(95% Cl 4.69-8.35)
Age- and sex-adjusted SMR across
three groups with different black-
foot disease prevalences (Taiwan
rates as reference)
Bladder cancer: nonendemic, SMRt
= 4.0; 0.1-5.0/1,000, SMRt =
18.0;5.0/1,000, SMR* = 40.0
Kidney cancer: nonendemic, SMRt
= 3.0; 0.1-5.0/1,000, SMRt = 7.0;
5.0/1,000, SMRt = 13.0
Skin cancer: nonendemic, SMRt =
2.0; 0.1-5.0/1,000, SMRt = 6.0;
5.0/1,000, SMRt = 110
Age- and sex-adjusted SMR (blackfoot
disease endemic area rates as
reference)
Bladder cancer: SMR = 2.55 (95%
Cl§ 1.43-4.21)
Kidney cancer: SMR = 1.60 (95%
Cl§ 0.33-4.68)
Skin cancer: SMR = 4.51 (95% Cl§
1.81-9.29)
* Under the assumption of independent occurrence; numbers are rounded,
t SMR, standardized mortality ratio; Cl, confidence interval.
t Estimated from logarithmic bar graphs, no measure of precision given.
§ Calculated from data.
exposed (3). In the later case-control study,
26 of 241 cases were in the group "none"
for years of artesian well water consump-
tion, but it is not clear how many of these
cases were exposed for less than a year and
how many not at all (20). Recall may also
have been problematic, because "duration
of drinking water since early childhood"
had to be remembered. Furthermore, water
may have been used for cooking but not for
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drinking. Finally, the study may have in-
cluded cases of ischemia due to traditional
causes (e.g., smoking, diabetes).
Is the association between arsenic in ar-
tesian well water and blackfoot disease a
causal one? In one case-control study (20)
and in a survey of 40,421 persons (13),
blackfoot disease co-occurred with cutane-
ous signs of arsenicalism to an extent un-
explainable by chance; nor can chance ac-
count for the higher mortality among
blackfoot disease patients from arsenic-
related skin cancer, as well as bladder and
kidney cancer. Is it possible that blackfoot
disease makes patients more likely to ex-
press cutaneous signs after arsenic expo-
sure and more susceptible to the cancers in
question? This reasoning cannot be rejected
as an explanation for some of the above
observations, but it would fail to explain the
dose-response relation between blackfoot
disease prevalence rates and arsenic content
in the deep wells (4). Another possibility is
that a component of drinking water other
than arsenic causes blackfoot disease. Hu-
mic substances have been proposed as such
a possibility.
Humic substances. Humic substances
in drinking water have been proposed to be
a cause of blackfoot disease (30). Initially,
it was reported that "ergotamine, D-lysergic
acid, and/or ergometrine might be present"
in water samples from the blackfoot disease
area (31). However, it is not clear whether
these findings have been confirmed, and
more recent studies do not mention ergota-
mine-like substances (30, 32-34). Rather, it
was pointed out that the complex composi-
tion of the well water prevents a detailed
chemical characterization (35). This is im-
portant, since the initial interest in humic
substances stemmed from the potent vaso-
constrictive effect of ergotamine (36).
While in vitro studies reported that the hu-
mic substances influence parameters of the
blood coagulation system (32-34) and cap-
illary permeability (23), no epidemiologic
data have so far been presented (37). Lu
(30) merely noted that "the intensity of the
fluorescence bore some relation to the in-
cidence of blackfoot disease," citing Lu et
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al. (38), where, in the English abstract, nine
correlation coefficients for fluorescent
characteristics are reported. However, the
derivation and interpretation of these corre-
lation coefficients was not presented, and
there is no indication that adjustment was
made for arsenic exposure.
An animal experiment which treated 16
male Balb/c mice with intraperitoneal in-
jection of fluorescent compounds dissolved
in deionized water over 22-23 days re-
sulted in "crippling, phlegmasia, ulceration,
necrosis, and gangrene in extremities" in
eight mice (39). Since no control mice were
used, no conclusion of causality can be
drawn from this study. In a much larger
series of 300 mice exposed to humic acids
in their drinking water for 24 months, gan-
grenous changes were not reported (40).
Because of the strong relation of black-
foot disease with arsenic exposure, the as-
sociation between humic substances and
blackfoot disease, and the relation between
arsenic and humic substances in water,
would have to be very strong for the arsenic
association to be the result of confounding.
In conclusion, the almost 20-year-old hy-
pothesis (38) that humic substances play an
etiologic role in blackfoot disease has not
been substantiated by epidemiologic or an-
imal studies. A causal role for arsenic in the
induction of blackfoot disease offers the
best explanation for the observations in
Taiwan.
Mortality due to vascular diseases
Wu et al. (17) conducted an ecoiogic
study involving 42 villages in six townships
in the endemic area (table 4). The choice of
villages was guided by the availability of
arsenic data. Rates of mortality from vari-
ous cancers and vascular diseases were an-
alyzed with respect to the median arsenic
level of water samples within a village.
Statistically significant trends were re-
ported for all vascular diseases together, for
cardiovascular but not cerebrovascular dis-
eases, and for diseases of the arteries, arte-
rioles, and capillaries (corresponding to
International Classification of Diseases,
Eighth Revision (40a) codes 440 through
TABLE 4. Relation between arsenic in well water and mortality from vascular diseases in an ecoiogic
study by Wu et al. (17); age adjusted mortality rates (per 100,000*), 1973-1986, and number of deaths
among residents 20 years and older, by median arsenic level
Median arsenic level
in well water
(mg/liter)
<0.3
0.3-0.59
£0.6
p value§
<0.3
0.3-0.59
S0.6
p value§
All vascular diseases
(401-448)t
Rate
* deaths
364.10 363
421.47 230
572.68 136
<0.001
277.50 320
370.79 226
386.41 93
<0.001
Causes of death
Diseases of arteries,
arterioles, and
capillaries
(440-448)t
"-* ZSL
Males
22.54 21
57.80 29
60.40 14
<0.001
Females
18.20 21
48.00 29
35.82 8
<0.05
Cardiovascular diseases
(410-414, 420-429)t
Rate*
125.87
153.98
259.51
No. of
deaths
127
85
62
<0.001
91.14
153.07
144.74
105
93
37
<0.001
Cerebrovascular
(430-438)t
Rate*
137.80
145.36
175.72
NSO
92.42
98.11
120.68
NSD
No. of
deaths
137
81
44
106
60
30
* Standard: 1976 world population.
t International Classification of Diseases, Eighth Revision, codes.
t Age-adjusted mortality rates.
§ p value for trend from Mantel extention test (29).
I NS, statistically not significant.
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448 referred to by Wu et al. (17) as periph-
eral vascular diseases). The authors' con-
clusion that peripheral vascular diseases
showed a dose-response relation with ar-
senic levels in well water has been criti-
cized on the grounds that no incremental
risk was observed between the moderate
and high exposure groups (41). Even as-
suming that the trends are real, questions of
interpretation arise. Since the deaths from
vascular causes included blackfoot disease
patients, these alone could explain the
trend. If so, no new knowledge would have
been conveyed. Based on the reasoning pre-
sented in the Appendix, we conclude that
this may be numerically possible. Another
scenario would be that "excess mortality
. . . was observed for residents in the study
area" (17), implying increased risks across
arsenic categories affecting residents inde-
pendently of blackfoot disease. The two
scenarios are not mutually exclusive.
While there are no reports contrasting
vascular mortality rates for the whole
blackfoot disease endemic area with the
Taiwanese general population rates, the
data from Chen et al. (20) can be used to
make such comparisons. In this study of
blackfoot disease patients, mortality rates in
both the blackfoot disease endemic area
and in all of Taiwan were used to generate
the expected number of deaths from each
cause. This allowed estimation of relative
risks for the blackfoot disease area com-
pared with Taiwan as a whole (table 5). The
resulting relative risks were 3.5 for diseases
of the arteries, arterioles, and capillaries,
1.3 for cardiovascular disease, and 1.1 for
cerebrovascular diseases. The vascular
mortality rates, based on residents of the
blackfoot disease endemic area, included
deaths of blackfoot disease patients. Un-
der the assumption that blackfoot disease
patients accounted for half of the deaths
due to diseases of the arteries, arterioles,
and capillaries, their subtraction from the
denominator still leaves a relative risk of
1.77 for the blackfoot disease area as a
whole compared with the entire country
of Taiwan.
In conclusion, while there is good epide-
miologic evidence supporting a causal as-
sociation between inorganic arsenic in well
water and occurrence of blackfoot disease,
the evidence for an effect on vascular dis-
ease mortality independent of blackfoot
disease is less compelling.
Reichenstein, Silesia
In 1898, Geyer (42) reported an in-
creased occurrence of gangrene ("Alters-
brand") in Reichenstein, Silesia (now part
of Poland). The population was exposed to
high levels of arsenic in the brooks (a level
of 12,000 ju,g/liter has been reported (1))
stemming from gold-containing arsenical
ores. Residents suffered from many signs
and symptoms of arsenicalism (disease of
Reichenstein), and there is an oral report
that "half of the patients . . . had died of
cancer" (1). A search for further informa-
tion from this area failed (43, 44).
TABLE 5. Standardized mortality ratio I (SMR I ) , based on Taiwan rates, and standardized mortality
ratio II (SMR II), based on blackfoot disease area rates, for 871 blackfoot disease patients in the study of
Chen et al. (20)
Disease SMR I (95% Cl*) SMR II (95% Cl) SMR I/SMR lit
Diseases of arteries, arterioles, and
capillaries (440-448)}:
Cardiovascular diseases (410-429)t
Cerebrovascular diseases (430-438)$
12.43(9.28-16.30)
2.09(1.70-2.55)
1.18(0.86-1.58)
3.51 (2.62-4.60)
1.60(1.30-1.95)
1.07(0.78-1.43)
3.54
1.31
1.10
• Cl, confidence interval (calculated from data).
t Dividing SMR I by SMR II results in the relative risks for the blackfoot disease area compared with Taiwan (i.e. SMR I/SMR
II = (Obs/ExpTifc>an)/(Obs/ExpBFDarea) = EXPBFD .rea/ExpTaiwan, where Obs = observed, Exp = expected, and BFD = blackfoot dis-
ease). The relative risks are the ratios of the two rates adjusted to the age structure of the blackfoot disease population (SMR I
and SMR II are comparable because they are standardized to the same population).
t International Classification of Diseases, Eighth Revision, codes.
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Latin America
Populations in Chile, Mexico, and Ar-
gentina have been exposed to levels of ar-
senic in drinking water comparable to those
from the blackfoot disease endemic area
in Taiwan. While there are some reports
of vascular manifestations, an occurrence
of gangrene and amputations comparable
to the magnitude found among blackfoot
disease patients in Taiwan has not been
described.
Chile. The inhabitants of the city of
Antofagasta were exposed to high levels of
arsenic in public drinking water for at least
12 years up to 1970 (45). In 1958, the need
for a larger supply led to the inclusion of
water from two rivers, which were found to
have elevated arsenic levels of around 600
jug/liter (46). After 1970, a treatment plant
reduced the arsenic content to levels around
the standard of 50 /Ag/liter.
The first cutaneous signs of arsenic poi-
soning in children were noted in 1962 (47).
After 1968, some patients showed vascular
spasm of the fingers, feet, and tongue with
histologic changes in accordance with
Raynaud's disease (hypertrophic media of
the artery). Several patients were reported
to have necrosis of the fingers, which in
some instances led to amputations (47).
Among 100 affected children, 19 had arte-
rial spasms in the fingers and toes. There
was one case of gangrene of a finger, and
four cases of ischemia of the tongue.
Raynaud's syndrome was found in 20 per-
cent of the boys and 17 percent of the girls
(48). Zaldivar (47) described five children
with cutaneous signs of arsenicalism who
died of vascular causes with involvement of
the coronary, cerebral, and mesenteric ar-
teries and the carotids. Intimal thickening
of the medium- and small-sized arteries in
many organs was found in five deceased
children investigated by Rosenberg (49),
who noted the resemblance of the his-
topathologic findings to reports from Tai-
wan. A report of two young, nonsmoking
males who suffered myocardial infarction
noted that one of them had progressive in-
termittent claudication and developed gan-
grene on a foot (50).
Among 166 patients with myocardial in-
farction who sought care at the Regional
Hospital of Antofagasta between 1967 and
1970, 30 (18.1 percent) were diagnosed
with chronic arsenic poisoning (47). Of
these, 30 percent were under the age of 40
years, compared with 5.9 percent of those
without arsenical signs at the same hospital
and 1.5 percent of 200 patients from a hos-
pital series in Santiago (51).
In a study of 180 persons from Antofa-
gasta, Borgono et al. (45) compared 144
persons with abnormal skin pigmentation
and 36 persons with normal skin.
Raynaud's syndrome (38.8 percent vs. 9.3
percent) and acrocyanosis (24.3 percent vs.
12.5 percent) were more prevalent among
those with skin abnormalities, who were
also more likely to have hyperkeratosis
(43.7 percent vs. 3.1 percent).
The population of the city of Antofagasta
in 1970 was 138,000, and in the whole
province 265,000 people were known to be
exposed to high arsenic levels in drinking
water (46). The population size and age
structure were similar to those of the black-
foot disease endemic area (13, 48). Chil-
dren and young adults had durations and
levels of exposure comparable to those in
Taiwan, where over a 2.5-year period in the
late 1950s, 17 cases of blackfoot disease in
children aged birth to 9 years and 46 cases
in children aged 10-19 years were diag-
nosed (5). One would expect a similar num-
ber of cases to have occurred in Antofa-
gasta by 1970, at least in the youngest age
group, where lifetime exposure would have
occurred. However, it was reported only
that "several cases had necrosis of the fin-
gers and required amputations"; actual
numbers were not presented (47).
Mexico. Chronic arsenicalism is en-
demic in some rural parts of the Region
Lagunera, located in northern Mexico. A
study comparing the clinical findings of
residents of El Salvador de Arriba (water
arsenic levels of 410-500 /xg/liter) with
those of residents of San Jose del Vinedo
(water arsenic levels of 1-5 /xg/liter) found
that in the exposed town, 22 percent (of 296
residents) had cutaneous signs of arsenical-
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ism, compared with 2.2 percent (of 318
residents) in the control town (52, 53).
Many additional symptoms of various or-
gans and systems were investigated (52).
However, no mention was made of periph-
eral vascular alterations, gangrene, or am-
putations. Given that 33 percent of resi-
dents suffered from skin disorders
considered precancerous, and that the ar-
senic content of the water was between the
medium and high categories of the wells in
Taiwan, one would expect around 10 cases
of blackfoot disease (an approximation
based on the rates from table 3).
In a short paper published later, 4 percent
of the exposed population were described
as having peripheral vascular alterations in
different stages of severity which led to
amputations in 0.7 percent of the cases
(54). However, it is not clear from the re-
port which population is being character-
ized, although from a personal communica-
tion with the author, it seems to correspond
to the same one described above. If so, two
of the 296 people sampled would have suf-
fered amputations.
In the Region Lagunera, there are 11
counties exposed to water with arsenic lev-
els ranging from 100 ju,g/liter to 500 jLtg/
liter, with an estimated population of
127,000 (55). This corresponds to at least
the low level in the Taiwanese studies (me-
dian: 170 ju,g/liter) (4). Although the signs
of arsenical skin disorders were very simi-
lar, there is no report of a comparable oc-
currence of blackfoot disease in the Mexi-
can exposed population of the Region
Lagunera.
A series of earlier papers (56-58) pre-
sented the results of a detailed study carried
out in two villages totaling 474 people in
the state of Coahuila. In one of the villages,
the only source of drinking water was a
well that reached arsenic levels of 3,980
/xg/liter (56). The study comprised environ-
mental and biologic exposure measure-
ments, as well as a comprehensive clinical
examination of a sample of 294 residents,
investigating 41 symptoms and other pos-
sible manifestations attributable to arsenic
intoxication (57). About 60 percent of the
population was considered affected (56).
Again, although all of the typical signs of
arsenical skin disease were commonly
found, in addition to many other systemic
symptoms of toxicity, no gangrene or am-
putations were reported.
Argentina. There are several regions in
Argentina known for having high levels of
arsenic in drinking water, with many re-
ports documenting the same types of skin
alterations found in other exposed popula-
tions. In particular, people from areas in the
provinces of Cordoba (59-63) and Salta
(64) have been affected. However, no sys-
tematic survey has been conducted to as-
sess the extent of arsenic-related diseases or
arsenic exposure in these areas.
The province of Cordoba had a popula-
tion of about 1.7 million in the early 1960s
(65), and arsenic in drinking water was
considered prevalent in a third of the area
of the province (66). Residents of one sur-
vey were exposed to drinking water with
levels ranging from 100 /Ag/liter to 1,200
/Lx-g/liter (61). A sampling of 60 water
sources taken from a vast area of the af-
fected region found arsenic levels ranging
from 18 jLtg/liter to 3,810 /xg/liter, with a
median of 410 ju,g/liter (67).
Most of the information on health effects
comes from publications by dermatologists,
such as Tello and Biagini, who have treated
many cases of arsenical skin disorders, vis-
ited the endemic areas, and followed their
patients for several years. In one series, 339
cases of skin cancer were diagnosed in per-
sons with clear manifestations of chronic
arsenic intoxication (62). In Belleville, Cor-
doba, 511 persons sought treatment in the
local hospital for arsenical disease between
1934 and 1944 (68). The population of the
town in 1990 was about 30,000 (H. B.
Nicolli, Comision Nacional de Investigatio-
nes Especiales, San Miguel-Bu.As., Argen-
tina, personal communication, 1992). If one
assumes that it was that high in 1940 (a
conservative estimate), almost 2 percent of
patients presented to one hospital. Clearly,
the extent of the problem was considerable.
However, there is no description of the
occurrence of peripheral vascular disease
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such as blackfoot disease in association
with arsenic in drinking water. In fact, re-
ports from Argentina state that the pathol-
ogy observed is different from that seen in
the Taiwanese, mainly because of the ab-
sence of blackfoot disease (62). In a recent
study in the province of Salta, angiographic
studies of the lower extremities of 12 pa-
tients suffering from dermatologic arsenic
disease were conducted (69). In all cases,
microangiopathies were observed, with ob-
struction of the terminal arteries. It was
noted that 66 percent of the patients were
under 50 years of age; half of those were
under age 25 years. However, no controls
were used. There was one reported case of
a leg amputation in a man from the endemic
arsenic area of Salta (69), but the possibility
of an underlying condition, such as diabe-
tes, was not addressed.
One of the authors of this paper (C. H.-
R.) communicated personally (in 1993)
with Drs. Tello (Cordoba, Argentina) and
Biagini (Hospital del Milagro, Salta, Ar-
gentina). They both stated that signs of
peripheral vascular disease were not appar-
ent in their case series, which included
many patients with arsenical skin disorders
from high arsenic areas.
Assessment. It is clear from the litera-
ture that in Mexico, Chile, and Argentina,
sizable populations have been exposed to
arsenic from drinking water. The skin dis-
orders of residents living in the affected
areas are typical of chronic arsenic toxicity,
and are similar to those found in Taiwan.
Regarding peripheral vascular alter-
ations, reports from Chile indicate the oc-
currence of Raynaud's syndrome and some
cases of acrocyanosis and necrosis of fin-
gers. In Mexico, none of the papers in
which extensive symptomatology of se-
verely intoxicated individuals was re-
viewed cited similar pathologies, except for
one short article reporting two cases of gan-
grene with amputation. In Argentina, pe-
ripheral vascular disease has not been ob-
served, although one recent study reported
microangiopathic changes in the extremi-
ties of patients with arsenical disease, as
revealed by arteriography.
In summary, although there are some in-
dications of peripheral vascular involve-
ment, they do not compare in magnitude or
severity to blackfoot disease in the endemic
area of Taiwan.
ARSENIC IN WINE SUBSTITUTES
Exposed populations
German vintners were heavily exposed to
inorganic arsenic between 1921 and 1942
through the application of arsenical pesti-
cides. While the spraying of grapes itself
only occurred on 1-14 days per year, sig-
nificant exposure occurred through inges-
tion of a "house drink" (Haustrunk) pre-
pared from the grape skins left over from
the first press (70). This low-alcohol bev-
erage was consumed throughout the year
and contained variably high levels of ar-
senic reaching up to 10 mg/liter. The wine
was also found to be contaminated with
arsenic: In Palatinate, 63 percent of 336
samples from 1938 contained more than 2
mg/liter, and of these, 43 percent had levels
over 5 mg/liter (70).
The occurrence of peripheral arterial dis-
eases has been reported from the wine-
making regions of Palatinate (70, 71) and
the Moselle area (72-75) and from Austria
(76). Signs of chronic arsenic exposure,
however, were first reported in the Kaiser-
stuhl region (South Baden) during the
1920s.
In Palatinate, among 80 cases with cuta-
neous signs of chronic arsenicalism be-
tween 1935 and 1945, 13 had severe pe-
ripheral arterial disease leading to
amputation of toes, with amputation below
the knee in two people and amputation of
both legs in two others (70). Amputation of
toes, and later of one leg below the knee, in
a hairdresser who never applied insecti-
cides but drank a substantial amount of
"house drink" was also reported (77).
In the Moselle area, Butzengeiger found
signs of peripheral arterial disease in 41
cases among 180 vintners with chronic ar-
senic intoxication around 1939 (72). Of
these cases, 20 reported coldness of the feet
and hands and seven were diagnosed with
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acrodermatitis atrophicans Herxheimer, a
rare cutaneous vascular disease with an in-
flammatory component. Six of the 15 that
were clinically diagnosed with peripheral
vascular disease showed gangrenous le-
sions, usually involving the hands and feet.
A 33-year-old individual who suffered
spontaneous amputation of the toes was
also afflicted with gangrene of the glans
penis. The median age of the 15 cases was
35 years, and only three cases were re-
ported to have reduced pulsation of the
dorsal arteries in the feet. Most cases were
moderate or light smokers. The main expo-
sure to arsenic was through "house drink"
and wine. Butzengeiger (73) subsequently
reported three more cases of gangrene of
the extremities, four cases of lesser circu-
latory problems, and two cases with acro-
dermatitis atrophicans among 36 vintners
with arsenic-induced electrocardiographic
changes. Among 24 autopsies conducted
between 1950 and 1956, thromboangiitis
obliterans in skin and esophagus specimens
were reported by Roth (74), who also de-
scribed a vintner who suffered amputation
of a leg at the age of 41 years.
A group of 100 surviving vintners were
followed up between 1972 and 1975, 30
years after cessation of arsenic exposure
(75). Acrocyanosis of arms and legs was
reported to have occurred with high fre-
quency (from 60 percent at age 50 years to
95 percent at age 95 years). Peripheral vas-
cular disease was prevalent, leading to one
amputation in a nonsmoker. It was men-
tioned that among the vintners not suffering
from arsenic intoxication, only 1-2 percent
suffered from vascular symptoms.
It was in the Moselle vintners that the
relation between arsenic and angiosarcoma
of the liver was first reported (78, 79).
Angiosarcoma of the liver is very rare; until
1981, there were fewer than 200 reports of
it (80). Additional cases of angiosarcoma in
association with arsenic have subsequently
been described (81-88).
In Austria, 22 vintners with cutaneous
signs of arsenicalism were described, one
of whom suffered from gangrene of a finger
(76).
Assessment
The clinical and pathologic vascular
changes described above were sufficiently
distinct from the atherosclerotic changes
observed in the elderly, leading clinicians
to strongly suspect that they were caused by
arsenic. Although the reports are not formal
epidemiologic studies and provide little in-
formation on selection of study subjects
and disease occurrence among the nonex-
posed populations, case series are informa-
tive in rare disease situations (89). The se-
vere peripheral vascular outcomes are rare
in the young age groups involved. Further-
more, the lesions occurred among vintners
with cutaneous signs of arsenicalism (70)
and among vintners under clinical surveil-
lance for chronic arsenic intoxication (72);
gangrenous lesions were not reported
among vintners prior to the use of arsenical
pesticides.
We believe that the most likely explana-
tion is a causal relation between arsenic and
the peripheral vascular alterations.
ARSENIC EXPOSURE VIA INHALATION
Occupational studies of workers ex-
posed to arsenic by inhalation have shown
strong and consistent associations with
lung cancer. The studies include several
occupations in different countries, includ-
ing sheep-dip manufacturing workers in
Britain (90); smelter workers in Ana-
conda, Montana (91-94), Tacoma, Wash-
ington (95-97), Salt Lake City, Utah (98),
Roennskar, Sweden (99-101), and Japan
(102); patients with signs of arsenic poi-
soning working in or living around an ore
mine with a refinery in Japan (103); and
insecticide manufacturers in Michigan
(104, 105) and Maryland (106). Most of
these studies present results regarding
mortality due to vascular diseases. Table
6 summarizes the risk ratio estimates for
various groups of circulatory diseases
from these investigations. The corre-
sponding risk ratios for lung cancer are
also shown for reference.
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TABLE 6. Occupational studies of arsenic inhalation with results for cardiovascular effects, and the
corresponding lung cancer risk ratios
Study
(reference no.)
Hill and Faning
(90)
Lee and Fraumeni
(91)
Lubin et al. (92)
Lee-Feldstein (94)
Welch et al. (93)
Pinto et al. (95)
Pinto et al. (96)
Enterline and
Marsh (97)
Rencher et al. (98)
Study
period
1910-1943
1938-1963
1964-1977
1938-1977
1938-1978
1946-1960
1949-1973
1941-1976
1959-1969
Cause of death Risk ratio(95% Cl*)t
Sheep dip manufacturing, Britain
Circulatory disease
Smelter, Anaconda, Montana
Heart disease (4O(M43)0
Cerebrovascular disease
(330-334)H
Circulatory disease
(390-458)H
Heart disease (410-414)11
Cerebrovascular disease
(430-438)11
Heart disease (400-443)#
Cerebrovascular disease
(330-334)#
Ischemic heart disease
(410-413)1)
Heavy exposure
Other exposure
Among smokers
Among nonsmokers
Cerebrovascular disease
(430-438)H
Heavy exposure
Other exposure
Smelter, Tacoma, Washingtoi
Cardiovascular disease
All workers vs. state
Exposed vs. unexposed
Heart disease (400-443)#
Coronary heart disease
(420)#
All other heart disease
Cerebrovascular disease
(330-334)#
Heart disease (440-443)#
Cerebrovascular disease
(330-334)#
Smelter, Salt Lake City, Utah
Circulatory disease
(390-458)1]
Smelter vs. mine
0.86(0.45-1.59)*
1.18(1.10-1.27)
1.10(0.93-1.29)
1.09(1.02-1.17)
1.08(0.99-1.17)
1.09(0.90-1.31)
1.30(1.23-1.37)
1.24 (1.10-1.40)
1.77(1.32-2.31)
1.37 (1.18-1.57)
1.47(1.26-1.70)
1.14(0.80-1.59)
0.87(0.32-1.89)
1.48 (1.12-1.93)
7
1.77(1.21-2.60)
1.36(0.46-4.89)*
1.09(0.92-1.28)
1.09(0.90-1.30)
1.09(0.70-1.62)
1.13(0.82-1.52)
0.93(0.84-1.02)
1.11 (0.90-1.37)
1.08**
Lung cancer
risk ratio
(95% Cl)t
4.47 (1.55-11.27)§
3.29 (2.78-3.87)
1.66(1.39-1.96)
2.85(2.54-3.19)
5.22 (3.34-7.76)
2.68 (2.02-3.48)
3.19(2.43-4.11)
2.05 (0.89-4.04)
3.05 (2.08-4.30)
1.95(1.59-2.37)
4.81**
TABLE 6. Continues
Sheep-dip workers
The study by Hill and Faning of workers
exposed to arsenical sheep-dip powder pro-
vided early evidence of elevated lung can-
cer risks (90). The age-unadjusted mortality
odds ratio for all circulatory diseases was
below unity, but about 40 percent of the
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TABLE 6. Continued
Study
(reference no.)
Axelson et al. (99)
Wall (100)
Jarupetal. (101)
Tokudome and
Kuratsune(102)
Tsuda et al.tt
(103)
Ottetal. (104)
Sobeletal. (105)
Mabuchi et al.
(106)
Study
period
1960-1976
1928-1977
1928-1981
1949-1971
1973-1989
1940-1973
1940-1982
1946-1977
Cause of death Risk ratio(95% Cl*)t
Smelter, Roennskar, Sweden
Circulatory disease
(410-412,427-428)
Exposed vs.unexposed
Circulatory disease
Ischemic heart disease
Cerebrovascular disease
(430-438)1)
Smelter, Japan
Heart diseases (393-398,
410-414,420-429)1]
Cerebrovascular disease
(430-438)1)
Ischemic heart disease
(41O-414)§§
Cerebrovascular disease
(430-438)§§
2.17 (1.10-4.36)tt
1.32(1.20-1.44)
1.07(0.97-1.18)
1.06(0.88-1.27)
0.47(0.19-0.97)
0.76(0.50-1.11)
2.14(0.86-4.40)
0.77(0.33-1.52)
Insecticide manufacturing, Michigan
Cardiovascular disease
Circulatory disease
(390-458)11
0.70 (0.50-0.95)
0.80 (0.65-0.98)
Insecticide manufacturing, Maryland
Circulatory disease
(390-458)H
Males
Females
Cerebrovascular disease
(430-438)1)
Males
Females
0.84(0.67-1.04)
1.19(0.74-1.82)
0.99(0.45-1.88)
2.16(0.79-4.66)
Lung cancer
risk ratio
(95% Cl)t
5.03 (2.21-11.44)tt
2.88 (2.27-3.60)
3.72 (3.05-4.50)
11.90(7.96-17.10)
5.67(2.45-11.20)
3.45(2.11-5.33)
2.25(1.56-3.12)
1.61 (1.03-2.40)110
* Cl, confidence interval.
t Risk ratio estimates are standardized mortality ratios if not otherwise indicated. Confidence intervals are recalculated (176,
177).
t Mortality odds ratio, excluding cancer deaths.
§ Mortality odds ratio, excluding other cancer and cardiovascular deaths.
I International Classification of Diseases, Sixth Revision, codes.
H International Classification of Diseases, Eighth Revision, codes.
# International Classification of Diseases, Seventh Revision, codes.
•• Comparative mortality figure, precision not estimable (but based on large numbers),
t t Odds ratio.
it Mortality experience of 141 arsenic poisoning patients around a smelter (worker and nonworker). Arsenic inhaled and
ingested.
§§ International Classification of Diseases, Ninth Revision, codes.
II Both sexes.
workers within the factory were in fact un-
exposed (ref. 90, table 4).
Smelter workers
The studies of the smelter workers in
Anaconda found elevated overall standard-
ized mortality ratios for heart and cerebro-
vascular diseases. However, no associa-
tions were found using surrogates for
arsenic exposure like length of employment
(91, 92), number of years at elevated expo-
sure (92), and period of first employment
(94). The analysis of a sample of 1,800 men
from the original cohort of 8,047 found
higher risks for ischemic heart diseases but
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not for cerebrovascular diseases among
those with "heavy" exposure (93). For is-
chemic heart diseases, the standardized
mortality ratio was higher in smokers, with
increasing standardized mortality ratios as-
sociated with increasing peak but not with
average arsenic exposure (ref. 93, table 12).
Workers in the Tacoma smelter showed
increased risk of dying of cardiovascular
diseases, especially at younger ages, in the
earliest study by Pinto et al. (95). In a
subsequent study (96) of 527 retirees, over-
all standardized mortality ratios were only
slightly elevated, and no further analyses
were presented. Enterline and Marsh (97)
did not find an overall effect for heart and
cerebrovascular disease in their study of
2,802 workers from the same cohort. Dose-
response analyses were reported only for
respiratory cancer.
The circulatory mortality rates (1959-
1969) were similar in smelter workers and
reportedly unexposed miners in a study by
Rencher et al. in Salt Lake City (98).
An early case-control study in Roennskar
reported an odds ratio of 2.17 for circula-
tory disease related to arsenic exposure,
with a statistically significant trend using
four levels of exposure (99). A subsequent
study found elevated standardized mortality
ratios for ischemic heart disease, other heart
diseases, and cerebrovascular diseases, re-
sulting in an overall standardized mortality
ratio for circulatory diseases of 1.32 (100).
A gradient for years of exposure and cere-
brovascular diseases was observed. In con-
trast, Jarup et al. (101) found much smaller
standardized mortality ratios for both is-
chemic heart diseases and cerebrovascular
diseases, with no trends being observed by
cumulative arsenic exposure. Physiologic
studies of vasospastic tendency have also
been conducted (107, 108). Increases in
vasospastic reactivity, as well as history of
Raynaud's phenomenon, were found in
men who worked at the smelter compared
with matched controls (107). It was con-
cluded in a later study that these vascular
effects of arsenic require long-term expo-
sure (108).
A study in Japan found standardized
mortality ratios for heart and cerebrovascu-
lar diseases which were below unity (102).
However, an excess risk for ischemic heart
disease mortality was found among 141
certified arsenic poisoning patients who
worked in or lived around a Japanese ore
mine (103). Arsenic exposure occurred by
both inhalation and ingestion. Among 125
arsenic poisoning patients from the same
area, 32 showed symptoms of Raynaud's
disease and two suffered gangrene in the
limbs (109).
Insecticide production
The studies of insecticide manufacturers
(104-106) did not report increased cardio-
vascular disease risks, with the exception of
an elevated but imprecise standardized
mortality ratio for cerebrovascular diseases
in females in one study (106).
Case reports
There are four case reports of vascular
symptoms following arsenic inhalation
(110-113) (table 7). Vascular manifesta-
tions ranged from symptoms of Raynaud's
disease (110) to penile artery thrombosis in
a 1-year-old infant (113). Exposure in the
latter occurred through ingestion, dermal
contact, and inhalation, and may have be-
gun in utero.
Assessment
It is difficult to draw inferences based on
these studies, since the results differ not
only across studies but also within study
populations. The pattern of increased lung
cancer risk ratios accompanied by in-
creased cardiovascular risk ratios is present
in the Anaconda and Roennskar studies, but
less so in the others. Most investigations
focused mainly on respiratory cancer and
did not attempt to analyze circulatory dis-
eases in much detail. However, it is inter-
esting that most relative risk estimates for
the smelter workers for the main subgroups
of circulatory diseases exceed unity, result-
ing in an overall standardized mortality ra-
tio for heart diseases of 1.16 (95 percent
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TABLE 7. Case reports
Study
(reference no.)
Kraetzer(110)
Oppenheim (111)
Kren(112)
Peters etal. (113)
Cannon (115)
Knoth(116)
Strauss (117)
Durck(118)
of vascular symptoms associated with arsenic inhalation and medication
Age
(years)
38
54
1
30
38
42
34
30
Sex
Female
Male
Male
Female
Female
Male
Male
Male
Exposure
Arsenic inhalation
Handling of arsenical
insecticides during 14
years
Wall paint containing 3 mg
arsenic per gram
(possibly arsine gas)
Wall paint high in arsenic
(possibly arsine gas)
Burning of chromium-
copper-arsenate con-
taining wood
Burning of chromium-
copper-arsenate
containing wood
Arsenic in medicines
Fowler solution for chorea
at age 12 years
Ingestion of arsenic
solutions for psoriasis
for 14 years
Inadvertent intramuscular
injection of 50% (instead
of 0.5%) arsenic solution
at age 20 years
Injection of 85 times the
maximum level of an
arsenic solution
Symptoms
Painful Raynaud
symptomatology
Multiple gangrene of the skin
(tibia)
Gangrene of toes and part of
calf
Thrombosis of penile artery
Placenta previa or abruptio
Raynaud syndrome,
exacerbation by cold
Amputation of leg due to
thromboangiitis obliterans
Progressive gangrene with
amputation of both legs
Loss of both legs
confidence interval (CI) 1.11-1.21) and for
cerebrovascular disease of 1.13 (95 percent
CI 1.03-1.23) (based on individual stan-
dardized mortality ratios derived from pre-
viously published studies (94, 97, 101-
103)). In addition, when analyses were
more detailed (e.g., taking into account
smoking status (93)), associations began to
appear that were previously undetected in
the same group of workers (91, 92, 94). The
case reports add limited but supportive ev-
idence of vascular disease associated with
arsenic inhalation.
In summary, we cannot rule out the pos-
sibility of a modest relative risk increase for
vascular disease in arsenic-exposed smelter
workers. Although small relative risks com-
bined with high background rates for vas-
cular diseases may be difficult to detect,
they may also indicate a significant public
health problem.
ARSENIC IN MEDICINES
Among the studies investigating the
health effects in patients treated with Fowl-
er's solution (1 percent potassium arsenite),
only one investigated vascular diseases.
The mortality experience in a cohort of 478
patients who received Fowler's solution be-
tween 1945 and 1969 was reported (114).
The standardized mortality ratios (SMR)
were below unity for all circulatory dis-
eases (SMR = 0.91, 95 percent CI 0.74-
1.1), for ischemic heart disease (SMR =
0.85, 95 percent CI 0.6-1.1), and for cere-
brovascular diseases (SMR = 0.72, 95 per-
cent CI 0.4-1.1). The standardized mortal-
ity ratios for diseases of the arteries,
arterioles, and capillaries are uninformative
because of the small numbers (J. Cuzick,
Imperial Cancer Research Fund, London,
England, unpublished data, 1992).
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In a subcohort of 142 patients with cuta-
neous signs of arsenicalism, the standard-
ized mortality ratio for all circulatory dis-
eases was 1.04 (95 percent CI 0.6-1.7), and
it was 0.81 (95 percent CI 0.4-1.4) in pa-
tients without such signs. The confidence
intervals are wide, but standardized mortal-
ity ratios for all causes, and particularly for
all neoplasms, were also higher in patients
with signs of arsenicalism.
In addition to the cohort study just de-
scribed, there are four case reports related
to medicinal arsenic exposure (table 7).
One woman had Raynaud's syndrome
(115) and three young men suffered ampu-
tations of legs (116-118), unusual events
for their ages. Fowler's solution (115, 116)
and inadvertent injection of arsenic solu-
tions (117, 118) accounted for the arsenic
exposure.
ANIMAL AND LABORATORY DATA
The metabolism, distribution, and elimi-
nation of inorganic arsenic differ across
species (119). Higher relative doses of ar-
senic are required to induce toxic effects in
animals than in humans (120), and animal
studies supply only limited evidence for
carcinogenicity (121). In view of the spe-
cies differences and the scientific focus on
the carcinogenic effects of arsenic, it is not
surprising that not much information can be
derived from available in vitro and in vivo
studies of the vascular effects.
The vascular effects of arsenic have been
investigated only sporadically in cell cul-
ture (122, 123), in perfused hindlegs prep-
aration of frogs (124) and rats (125), and in
whole animals (126). One in vitro study
suggested that human umbilical endothelial
cells may be damaged by arsenite (122),
and in another study, arsenite-induced dam-
age of endothelial cells from bovine carotid
arteries was reduced by pretreatment with
glutathione, the protective effect of which
may have been mediated by prostacyclin
(123). The feeding of high doses of triva-
lent arsenic (125, 126) and artesian well
water from the blackfoot disease area (124)
led to an increase in vascular resistance.
Overall, the information derived from these
studies is limited. There is no established
animal model for the vascular effects of
arsenic. Ideally, a good animal model
would be analogous to the Watanabe heri-
table hyperlipidemic rabbits, which al-
lowed the elucidation of cholesterol metab-
olism and whose pattern of atherosclerosis
is indistinguishable from the human coun-
terpart (127). Currently, therefore, the
available evidence stems almost exclu-
sively from epidemiologic data.
DISCUSSION
So far, the discussion of the evidence
relating arsenic to vascular disease has re-
mained within exposure source and ex-
posed groups. Now, we will investigate the
similarities and differences between the ex-
posed populations, with particular interest
in the differences between groups with re-
spect to the presence or absence of gan-
grene and amputations.
Severe peripheral vascular disease with
gangrene and amputations: possible
explanations of inconsistencies
In the preceding sections, we have ar-
gued that a causal role for arsenic offers the
best explanation for the occurrence of
blackfoot disease in Taiwan and the occur-
rence of gangrene and amputations among
the German vintners. The combined evi-
dence from these two populations, together
with other reports of gangrene or amputa-
tions (42, 47, 48, 50, 54, 69, 109, 111, 112,
116-118), provides good epidemiologic
evidence for a causal role for arsenic. How-
ever, in terms of the frequency of gangrene
and amputations, there are important differ-
ences between populations, with high oc-
currence in Taiwan and among German
vintners, occasional reports from Latin
America and Japan, and the absence of
reports from smelter workers and a cohort
of patients receiving Fowler's solution.
Arsenic dose. Bates et al. (ref. 2, table
5) have estimated and compared the
cumulative total dose for the four types
of arsenic-exposed populations described
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above. Moselle vintners, residents of the
blackfoot disease area, high-exposure
smelter workers, and Fowler's solution pa-
tients were estimated to have ingested or
inhaled 17.5-175.2 g, 30 g, 6.8 g, and 2.8 g,
respectively. The ingested total dose was
far higher for German vintners and resi-
dents of the blackfoot disease area than
for smelter workers and Fowler's solution
patients. Populations in Chile, Mexico,
and Argentina were exposed to levels of
arsenic in drinking water comparable to
those in the blackfoot disease endemic
area in Taiwan.
While the arsenic dose may explain the
absence of gangrene and amputations
among the smelter workers and Fowler's
solution patients, low occurrence of these
conditions in several Latin American coun-
tries warrants the exploration of alternative
explanations. If arsenic is a causative fac-
tor, then there must be other necessary fac-
tors (or absence of protective factors) that
are more prevalent in the blackfoot dis-
ease area and among German vintners
than in the Latin American populations.
One such differentiating factor may be
nutritional status.
Nutrition (zinc). Yang and Blackwell
(24), suspecting the importance of dietary
factors in the etiology of blackfoot disease,
discussed the "miserable nature" of the res-
idents' diet in the late 1950s, which con-
sisted, in large part, of dried sweet potatoes.
These authors hypothesized that the diet
may have been lacking in essential fatty
acids, and reported that the residents' intake
of methionine was inadequate. Reference
standards for amino acids have, however,
been changed, and by today's standard the
intake of sulfur-containing amino acids was
adequate (2). The possibility of a marginal
deficiency of essential fatty acids remains.
Yang et al. (128) further tested the ade-
quacy of the local diet by comparing the
growth of rats raised on either the local diet
or a control diet. The usual diet from the
blackfoot disease area did not support ade-
quate growth in rats, and this effect was
independent of the presence of well water
residue.
Epidemiologic evidence for a role of nu-
trition in blackfoot disease comes from the
case-control study by Chen et al. (20),
where high consumption of dehydrated po-
tatoes and low consumption of eggs, meat,
and vegetables were found to be risk fac-
tors. Engel and Receveur (129) have calcu-
lated the nutrient intake in this population
based on the aggregated food consumption
data presented by Yang and Blackwell (24).
The results indicate that zinc intake may
have been inadequate, with an average
daily intake of 58 percent of the Recom-
mended Dietary Allowance (130). The pos-
sibility of a role for marginal zinc intake in
blackfoot disease is supported by reports of
low zinc levels in whole blood, plasma,
urine (131), and hair (132) in blackfoot
disease patients compared with controls. In
another study, blood zinc levels were also
lower in blackfoot disease patients, but the
difference was not statistically significant
(133).
There are reasons to believe that German
vintners may have had a marginal zinc sta-
tus as well, because of mechanisms involv-
ing alcohol consumption and factors inhib-
iting zinc absorption. The alcohol
consumption of the German vintners was
very high. In addition to wine, daily con-
sumption of several liters of "house drink"
(2-5 percent alcohol) was common. Liver
damage and cirrhosis occurred with high
frequency (70). High urinary zinc excretion
has been reported in alcoholics (134), but it
is an open question whether hypozincemia
and hyperzincuria, often observed in liver
cirrhosis, are caused by the effect of ethanol
on zinc metabolism or via liver damage
(135). Arsenic itself can damage the liver
(136).
The "house drink" may have contained
substances that inhibit zinc absorption, such
as copper (137, 138). The arsenical pesti-
cides used by the vintners were often cop-
per compounds (70). The house drink re-
sulted from applying high pressure to
aqueous infusion of the grape skins and the
stems (77). This process may have resulted
in the presence of appreciable amounts of
lignin and hemicellulose. The high lignin
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content of the grape skin hinders its use in
animal feed because it reduces digestibility
(139), and the particular types of fibers
present in grape skins (lignin and hemicel-
lulose) have also been reported to inhibit
zinc absorption in humans (140, 141).
We are not aware of a detailed nutritional
assessment of the Latin American popula-
tions. Information concerning Argentina in-
dicates that rich agriculture and cattle rais-
ing were characteristic of the region (65).
The nutritional difference between the peo-
ple of Argentina and Taiwan has been pos-
tulated as a possible explanation for the
lack of blackfoot disease in Argentina,
given that the diet there has a high protein
content (62). However, it may be fitting
that the affected children in Antofagasta,
Chile, were of very low socioeconomic
class and were reported to have nutritional
deficiencies (48). The population in Mexico
that was living in areas of arsenic-contam-
inated water had poor living and sanitary
conditions (56).
Biologic plausibility for a role of
marginal zinc status
At present, a detailed knowledge of the
biologic bases for the vascular effects of
chronic arsenic exposure is lacking, and the
mechanisms by which arsenic causes can-
cer are not clearly understood. We never-
theless shall attempt to describe several
possible mechanisms through which a mar-
ginal zinc status could play a role in the
severe vascular manifestations of chronic
arsenic exposure with its atherosclerotic
and thrombotic manifestations (22, 49, 74).
These mechanisms may act independently
or in concert, and include an imbalance of
damage (arsenic) and repair (zinc), a pro-
tective effect of zinc on endothelial mem-
branes and against actions of cytokines,
decreased levels or activities of glutathione,
glutathione S-transferase and superoxide
dismutase, indirect competition of arsenic
with zinc in proteins containing vicinal
dithiols, and decreased intracellular avail-
ability of zinc through sequestration by
arsenic-induced metallothionein. These
mechanisms, with the exception of those
acting on endothelial cells, may also be
relevant to arsenic carcinogenicity. If so,
then blackfoot disease patients would be
at greater risk of developing arsenical
cancer because of their increasing loss
and requirement of zinc.
On a general level of explanation, there
may be an ever-increasing imbalance be-
tween damage by arsenic and attempted
repair requiring zinc during the course of
the condition. In this sense, the gangrene
itself, once started in patients with marginal
zinc status, would increase zinc require-
ments for repair purposes (137), resulting in
a self-perpetuating disease state.
Low zinc could make endothelial cells
more vulnerable to arsenic, because zinc
appears to be important in vascular endo-
thelial barrier function (142, 143) and
membrane integrity in general (144).
Cytokines display effects on endothelial
cells (145), among which we consider tu-
mor necrosis factor a candidate for mediat-
ing arsenic-induced gangrene, because tu-
mor necrosis factor is involved in
endotoxin-mediated intravascular coagula-
tion and tissue necrosis (Shwartzman reac-
tion). Zinc has been reported to inhibit tu-
mor necrosis factor-induced disruption of
endothelial cell integrity (142) and tumor
necrosis factor-mediated DNA fragmenta-
tion and cytolysis of murine cells (146).
Glutathione levels inversely correlate
with arsenic toxicity in a variety of systems
(123, 147-150), including bovine endothe-
lial cells (123). Glutathione is involved in
arsenic methylation (151) and may stimu-
late prostacyclin (an inhibitor of platelet
aggregation and smooth muscle cell prolif-
eration) in arsenic-exposed endothelial
cells (123). In zinc-deficient rats, blood
glutathione levels were lower than in pair-
fed controls (152, 153). Following zinc
treatment, glutathione levels increased in
Chinese hamster ovary cells (154) and in
rat hepatocytes (155). With respect to the
protective effect of prostacyclin (123), it
is interesting that the possibility was
raised that zinc deficiency may decrease
the number of prostacyclin receptors of
the vasculature (156).
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Arsenic resistance in Chinese hamster
ovary cells is associated with increased glu-
tathione 5-transferase activity (149, 157,
158). In zinc-deficient rats, glutathione 5-
transferase activities were decreased (159,
160), and were restored following zinc re-
plenishment (159). Zinc given subcutane-
ously increased glutathione 5-transferase
activity in mice (161), and glutathione S-
transferase activity increased in Chinese
hamster ovary cell lines following zinc
treatment (154, 157).
Oxygen radicals may be involved in ar-
senite-induced damage, for the addition of
the radical-scavenging enzyme superoxide
dismutase decreased the frequency of ar-
senite-induced sister chromatid exchanges
in human peripheral lymphocytes (162). In
rat liver cells, the activity of superoxide
dismutase increased upon incubation with
physiologic zinc levels (155).
Finally, on a molecular level, arsenite
may indirectly compete with zinc in metal-
binding proteins displaying vicinal dithiols
contained in zinc fingers of DNA binding
and repair proteins and transcription factors
(163, 164) and in protein kinase C (which
can be activated by tumor promoters such
as phorbol esters) (165). Zinc finger in one-
proteins have been proposed as targets for
nickel, cobalt, and cadmium carcinogenic-
ity (163, 166). Likewise, vicinal dithiols in
zinc fingers have been proposed as targets
for arsenite, implying the proteins' confor-
mational change and altered biologic func-
tion (167,168). Arsenite has been shown to
bind in vitro to vicinal dithiols in the rat
glucocorticoid receptor (169-171). While
it is unlikely that arsenite can replace zinc
ions from their position in already formed
motifs, we speculate that arsenite may
sometimes occupy the zinc binding site
during protein synthesis or immediately
following translation of the protein before
zinc can be embedded into the site in a low
zinc environment, especially when intracel-
lular zinc availability may be further de-
creased by sequestration of zinc by metal-
lothionein (172), which is inducible in vivo
by arsenite (168) but is unknown to protect
cells from arsenic (157).
Mortality due to vascular diseases
Mortality has been studied in the black-
foot disease area (17) and among workers
exposed through inhalation. No clear infer-
ences can be drawn from these studies.
While there is indirect evidence that mor-
tality rates due to diseases of the arteries,
arterioles, and capillaries are higher in the
blackfoot disease endemic area, the re-
ported trends across arsenic categories for
these diseases, as well as for cardiovascular
diseases (17), could have been due to the
mortality experience of blackfoot disease
patients. While the results of smelter
worker studies are interesting in that the
pooled standardized mortality ratios for
heart diseases and cerebrovascular diseases
are above unity, they are not informative
enough to allow for causal inference.
However, one can view gangrene and
amputation as the tip of an iceberg, as a
visible expression of a systemic disease.
This view is supported by reports of high
mortality due to vascular causes among
blackfoot disease patients (20); of athero-
sclerotic changes of internal arteries and
arterioles in blackfoot disease patients (3,
22), German vintners (71, 74), and chil-
dren from Antofagasta (49); and of
Raynaud's disease symptoms or acrocya-
nosis in smelter workers (107, 108), per-
sons exposed to drinking water (45), per-
sons living around a smelter (109), and
German vintners (75).
CONCLUSION
There is good epidemiologic evidence
that chronic arsenic consumption at high
levels is a cause of severe peripheral vas-
cular conditions with resulting gangrene
and amputations of the limbs. We hypoth-
esize that marginal zinc status may explain
the differential occurrence of these severe
conditions in populations ingesting large
doses of arsenic. It is plausible, though
there is limited epidemiologic evidence,
that arsenic may cause increases in vascular
mortality beyond that in patients with se-
vere peripheral vascular disease.
204 Engel et al.
We believe that vascular effects should
be included in the future study of the health
effects of arsenic. The possible synergistic
role of marginal zinc status in atherogenesis
and carcinogenesis should be investigated,
because zinc may constitute an easily ad-
ministered preventive factor. Despite the
known adverse health effects of arsenic, an
estimated 112,000 (173) to 347,000 (174)
persons in the United States are exposed to
levels exceeding the maximum contami-
nant level of 50 jug/liter in US water sup-
plies (174), and other populations in Latin
America, Taiwan, and Eastern Europe
(175) are also exposed to high levels. The
large number of people still exposed illus-
trates the potential public health benefit of a
preventive factor.
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APPENDIX
Trends in mortality within the blackfoot
disease endemic area may be due to
blackfoot disease patients
In the paper by Wu et al. (17), 27 of the 42
villages included in the study were in the four
townships of Peimen, Hsuechia, Putai, and
Ichu, and 15 villages were in the two townships
of Yensui and Hsiaying, all in Taiwan. In the
latter two townships, most villages were in the
lowest arsenic category (ref. 17, figure 1), and
according to the map in the paper by Ch'i and
Blackwell (ref. 3, figure 3), only four cases
occurred there by 1963. This pattern of villages
falling into the low arsenic category coinciding
with low occurrence of blackfoot disease is
repeated for the northern villages in Ichu and
the eastern villages of Hsuechia. Most blackfoot
disease patients resided, therefore, in villages in
the middle and high arsenic categories. A trend
might have been created by blackfoot disease
patients who died of the particular cause in the
two higher categories. The number of blackfoot
disease patients and their causes of death (20,
21) are such that they may account for excess
rates in the middle and higher arsenic catego-
ries. Gangrene accounted for 12.4 percent of
deaths and heart diseases for 19.8 percent of
deaths in 864 deceased blackfoot disease pa-
tients (21) between 1958 and 1982. Under the
assumption that 36 patients die each year, one
would expect 468 deaths during the period
1973-1986, resulting in 58 (12 percent) dying
of gangrene and 93 (19.8 percent) of heart dis-
eases. Based on the visual inspection of the two
maps (ref. 17, figure 1, and ref. 3, figure 3) and
the person-years of observation in the middle
and higher arsenic categories (ref. 17, table 1),
we estimate that half of the mortality of
blackfoot disease patients was included. If so,
the mortality experience of blackfoot disease
patients may account for the observed trends,
since 30 of the 80 deaths due to diseases of
the arteries, arterioles, and capillaries and 45
of 277 deaths due to cardiovascular disease
could be attributed to deceased blackfoot dis-
ease patients.
